1-4 of 4
Tarek Ebrahim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mode of Nipocalimab Action and Pharmacology in Cells and Preclinical Models

Amit Choudhury, Wim Noël, Tarek Ebrahim, Cathye Shu, Leona E Ling, Bruno Fattizzo
Journal: Blood
Blood (2022) 140 (Supplement 1): 8161–8162.
https://doi.org/10.1182/blood-2022-165381
Published: 2022
Journal Articles

Energy Trial in Warm Autoimmune Hemolytic Anemia (wAIHA): Design of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Blocker

Irina Murakhovskaya, Bruno Fattizzo, Tarek Ebrahim, Kristen Sweet, Cathye Shu
Journal: Blood
Blood (2022) 140 (Supplement 1): 2443–2444.
https://doi.org/10.1182/blood-2022-165585
Published: 2022
Journal Articles

Pharmacokinetics and Pharmacodynamics of Nipocalimab Administered at Different Rates of Intravenous Infusion in Healthy Participants: Results of a Phase 1 Placebo-Controlled Single-Dose Study

Jocelyn H. Leu, An Vermeulen, Tarek Ebrahim, Leona E. Ling
Journal: Blood
Blood (2022) 140 (Supplement 1): 11039–11040.
https://doi.org/10.1182/blood-2022-165564
Published: 2022
Journal Articles

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

Clinical Trials & Observations
David C. Dale, Frank Firkin, Audrey Anna Bolyard, Merideth Kelley, Vahagn Makaryan, Kenneth J. Gorelick, Tarek Ebrahim, Varun Garg, Weihua Tang, Honghua Jiang, Renato Skerlj, Sarah Beaussant Cohen
Journal: Blood
Blood (2020) 136 (26): 2994–3003.
https://doi.org/10.1182/blood.2020007197
Published: 2020
Includes: Supplemental data